Genmab: Revenue may exceed DKK 20bn in 2024
Genmab expects that the company’s revenue in 2024 can grow by 19% and land in the range of DKK 18.7 to 20.5bn (USD 2.69-2.95bn).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analysts expect increased 2024 costs at Genmab
For subscribers
Investors look for pipeline news in upcoming Genmab report
For subscribers